62391-99-5Relevant articles and documents
Preparation method of 2-R1 valeric acid
-
Paragraph 0051; 0058-0060, (2021/07/24)
The invention discloses a preparation method for 2-R1 valeric acid. The preparation method comprises the following steps: step 1, with methyl cyanoacetate as a starting material, adding bromopropane and sodium methoxide, carrying out a catalytic reaction, and conducting purifying to obtain 2-cyanomethyl valerate; step 2, subjecting 2-cyanomethyl valerate to a reaction under the catalysis of iodoalkane and sodium methoxide, and conducting aftertreatment to obtain 2-cyano-2-R1 methyl valerate; step 3, enabling the 2-cyano-2-R1 methyl valerate to undergo a reaction in an aqueous solution of sulfuric acid at 120-160 DEG C for 15-40 hours so as to obtain a mixture of 2-R1 valeric acid and 2-R1 methyl valerate; and step 4, hydrolyzing the mixture by using an aqueous sodium hydroxide solution to obtain 2-R1 sodium valerate and methanol, and conducting acidifying by using inorganic acid to obtain 2-R1 valeric acid. Reagents adopted in the preparation method are relatively common, and the risk of the reagents is relatively low; and reaction conditions are mild, and the temperature is easier to control relatively. The invention develops a purification process of the key intermediate 2-cyanomethyl valerate, and the process flow is simple.
Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates
Hen, Naama,Bialer, Meir,Yagen, Boris
experimental part, p. 2835 - 2845 (2012/06/15)
A novel class of 19 carbamates was synthesized, and their anticonvulsant activity was comparatively evaluated in the rat maximal electroshock (MES) and subcutaneous metrazol (scMet) seizure tests and pilocarpine-induced status epilepticus (SE) model. In spite of the alkyl-carbamates' close structural features, only compounds 34, 38, and 40 were active at the MES test. The analogues 2-ethyl-3-methyl-butyl-carbamate (34) and 2-ethyl-3-methyl-pentyl- carbamate (38) also exhibited potent activity in the pilocarpine-SE model 30 min postseizure onset. Extending the aliphatic side chains of homologous carbamates from 7 to 8 (34 to 35) and from 8 to 9 carbons in the homologues 38 and 43 decreased the activity in the pilocarpine-SE model from ED50 = 81 mg/kg (34) to 94 mg/kg (35) and from 96 mg/kg (38) to 114 mg/kg (43), respectively. The most potent carbamate, phenyl-ethyl-carbamate (47) (MES ED50 = 16 mg/kg) contains an aromatic moiety in its structure. Compounds 34, 38, 40, and 47 offer the optimal efficacy-safety profile and, consequently, are promising candidates for development as new antiepileptics.
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues
Kaufmann, Dan,Bialer, Meir,Shimshoni, Jakob Avi,Devor, Marshall,Yagen, Boris
experimental part, p. 7236 - 7248 (2010/07/04)
Valproic acid (VPA, 1) is a major broad spectrum antiepileptic and central nervous system drug widely used to treat epilepsy, bipolar disorder, and migraine. VPA's clinical use is limited by two severe and lifethreatening side effects, teratogenicity and hepatotoxicity. A number of VPA analogues and their amide, N-methylamide and urea derivatives, were synthesized and evaluated in animal models of neuropathic pain and epilepsy. Among these, two amide and two urea derivatives of 1 showed the highest potency as antineuropathic pain compounds, with ED50 values of 49 and 51 mg/kg for the amides (19 and 20) and 49 and 74 mg/kg for the urea derivatives (29 and 33), respectively. 19, 20, and 29 were equipotent to gabapentin, a leading drug for the treatment of neuropathic pain. These data indicate strong potential for the above-mentioned novel compounds as candidates for future drug development for the treatment of neuropathic pain. 2009 American Chemical Society.
